DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Phase 2

Not yet recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BI 1015550
Drug: Pirfenidone

First Posted Date: 2024-02-05

Last Posted Date: 2025-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT06241560

Locations: 🇬🇪
LTD The First Medical Center, Tbilisi, Georgia
🇬🇪
LTD "Aversi clinic", Tbilisi, Georgia

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Phase 3

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis

Interventions: Drug: BI 1015550

First Posted Date: 2024-02-02

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1700

Registration Number: NCT06238622

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 371 locations

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765423
Drug: Placebo matching BI 765423

First Posted Date: 2024-01-30

Last Posted Date: 2025-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT06232252

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: survodutide
Drug: Placebo matching BI 456906

First Posted Date: 2024-01-22

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 307

Registration Number: NCT06214741

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Beijing Pinggu Hospital, Beijing, China

and more 27 locations

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Drug: BI 456906
Drug: Placebo to BI 456906
Drug: Moxifloxacin
Drug: Placebo to moxifloxacin

First Posted Date: 2024-01-11

Last Posted Date: 2025-03-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 110

Registration Number: NCT06200467

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib

Completed

Conditions: Idiopathic Pulmonary Fibrosis
Diarrhoea

First Posted Date: 2024-01-11

Last Posted Date: 2025-05-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 17

Registration Number: NCT06200714

Locations: 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Spain
🇪🇸
Hospital de La Princesa, Madrid, Spain
🇪🇸
Hospital Clínico San Carlos, Madrid, Spain

and more 5 locations

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Avenciguat (BI 685509) (intended commercial formulation (iCF))
Drug: Avenciguat (BI 685509) (trial formulation 2 (TF2))
Drug: esomeprazole

First Posted Date: 2024-01-05

Last Posted Date: 2024-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06193811

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Survodutide
Drug: Placebo matching survodutide

First Posted Date: 2023-12-19

Last Posted Date: 2025-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT06176365

Locations: 🇯🇵
Shimamura Kinen Hospital, Tokyo, Nerima-ku, Japan
🇯🇵
Chiba University Hospital, Chiba, Chiba, Japan
🇯🇵
Hosokawa Surgery Clinic, Aichi, Nagoya, Japan

and more 25 locations

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583
Drug: [14C]-BI 1291583

First Posted Date: 2023-12-12

Last Posted Date: 2024-02-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06166992

Locations: 🇳🇱
ICON, Groningen, Netherlands

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3

Recruiting

Conditions: Lung Cancer, Non-squamous, Non-small Cell

Interventions: Drug: pembrolizumab
Drug: zongertinib
Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2023-11-30

Last Posted Date: 2025-05-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 270

Registration Number: NCT06151574

Locations: 🇫🇷
HOP Civil, Strasbourg, France
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Mohtaseb Cancer Center and Blood Disorders, LLC, Bullhead City, Arizona, United States

and more 164 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy